Integumen Share Discussion Threads

[buywell3] 27/11/2018 21:22

Meta Tags - How Google Meta Tags Impact SEO




It’s important to note that the description tag won’t always show up in the results for a Google search (Google frequently picks a snippet of text from the page itself) but it’s useful in other ways. Google has also stated that keywords in meta descriptions won’t affect your rankings. However, a compelling meta description tag could entice searchers to click through from the SERP to your site, especially if the description includes the keywords they were searching for.

Google’s reasons are somewhat mysterious, but their actions speak loudly: meta keywords don’t much matter anymore, but meta descriptions most certainly do.

Good link the one above is ... and the Meta Description Para's are especially noteworthy

Meta Description Attribute

This is a quite useful meta tag as, very simply, it explains to search engines and (sometimes) searchers themselves what your page is about. Let’s say you were googling the phrase “meta keywords” for example. You might encounter the following results:

It’s important to note that the description tag won’t always show up in the results for a Google search (Google frequently picks a snippet of text from the page itself) but it’s useful in other ways. Google has also stated that keywords in meta descriptions won’t affect your rankings. However, a compelling meta description tag could entice searchers to click through from the SERP to your site, especially if the description includes the keywords they were searching for.

Google’s reasons are somewhat mysterious, but their actions speak loudly: meta keywords don’t much matter anymore, but meta descriptions most certainly do.

[yump] 27/11/2018 17:49

I don't have an investment here, but I have to comment on the use of the internet to gain customers as I have getting on for 15 years of experience of using pay-per-click advertising for my own business.

Firstly, EVERY SEO business will insist that they can get your business up higher on Google. However, given the increasingly limited space available to see your business listed, due to the rise of the mobile, that is a time consuming and expensive process with no guarantee of results or sustained results, even if there is some success. Its partly an act of faith to spend money on SEO.

However, from a business point of view, a 'natural' Google listing is not the only option, although loads of people think its the holy grail. Which it is if you're lucky.

If you use pay-per-click advertising and the ROI is right, you have a scalable and profitable means of gaining new customers. If you pay enough per click, you can get the top result. If your ROI is OK, then you've basically got a scalable formula that is pretty much like a management game, where if you double your spend, you double your profits.

and the whole process is EXACTLY measurable from day 1.

gjb
PM me if you like, if you've only been 'sold' SEO and not pay-per-click. If the SEO people do PPC, then they'll probably provide that. If they don't, they're unlikely to promote it, as potentially you could then do without them.

[buywell3] 27/11/2018 15:56

The Direct Peptide Reactivity Assay (DPRA) and the KeratinoSensTM are the first non-animal tests adopted on 5 February 2015 by the OECD to identify skin sensitisers.

The OECD Test Guidelines 442C provides an in chemico procedure to address the molecular initiating event which is the covalent binding of electrophilic substances to nucleophilic centres in skin proteins.

The TG 442D describes the KeratinoSensTM test method, to address inflammatory
responses as well as gene expression associated with specific cell signalling pathways such as the antioxidant/electrophile response element (ARE)-dependent pathways.



The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM)has validated and recommended a new method, the human Cell Line Activation Test (h-CLAT)on March 2015.

The h-CLAT measures the upregulation of the CD86 and CD54 markers of dendritic cells (DC) in THP-1 cells, a human monocytic leukemia cell line.

This addresses the activation of DC within the AOP


In vitro and in chemico methods used in combination with in silico models within Integrated Approaches to Testing and Assessment (IATA) (such as the ITS-2, using a Bayesian network to analyze data, or the Unitis NCS TOX project, aiming to build a predictive database to determine the toxicological profile of Natural Complex Substances, …) may provide sufficient information to allow the identification of potential skin allergens and the characterization of their relative potency.


buywell

So it looks like EU wise a combo of an in-vitro tests together with an in-silico tests is the way the EU is going.

in-silico means computer predicted modelling ie Labskin AI

[buywell3] 27/11/2018 02:54

................. Labskin :- an uncommercialized gem .......................


.................. Is it now set to sparkle ? ....................





Evocutis made the mistake of selling Labskin kits to clients for them to do the testing themselves.

Which meant that they sold themselves short by missing out on the added value that was there if Evocutis had of carried out the in vitro testing for the clients and provided a 'one stop shop ' service.

Daft

No wonder Evocutis went under after spending millions on developing Labskin ... and then not commercializing it sales wise.


But , and correct me if I am wrong Integumen under the olde CEO picked up where Evocutis left off and sold Labskin kits to customers.


I do so hope that this practice has STOPPED

If it has not then IMO it should be stopped NOW and no further kit orders taken

Evocutis has proved that this was not the way to go and the olde Inegumen CEO didn't learn from it.

I expect GB has already got this one sorted

Added value is king as is riding the current wave of testing requirements that are flooding in from the Cosmetics Industry ... pedal to the metal ... shift work ... working weekends .... all these things need looking at when offering new contracts to staff .... busy busy busy ... 24hrs 7 days a week .... while the demand is there.


I am talking about a backlog of demand re FDA looking at the Cosmetics Industry


Now is the time to make some serious lolly


In the future , say 2 years from now ... when things have become a bit more clearer re the FDA ... and IMO for sure they will get involved in the approval process of Cosmetics products ... clients gained now by Integumen by using Labskin in-vitro testing / Labskin AI or both I hope , could well remain SKIN customers to be then sold SKIN services to meet whatever FDA requirements are put in place.


As long as SKIN undercut the pricing of this company or the pricing of the CRO's that use it , Labskin should continue to gain market share IMO



think Matek carries out no in house in-vitro testing , but uses/pertners/sells to other CRO's

eg




It just might be that Integumen is the only maker of a human skin equivalent that carries out its own in-house in-vitro testing services ... if that is right its a good one for marketing purposes


They need to get the www.labskin.co.uk website sorted to drive enquiries though as my next post shows

[dave4545] 26/11/2018 14:08

Ah yeah welcome.

It will not take much to get this moving in the right direction, last few T10's from the spike 11 days ago are still selling out but not many if any left now.

[supertag] 26/11/2018 14:05

went to NT when I tried to buy in one go and thought it might cost me more so split.
Hoping for some upward movement soon.

[supertag] 26/11/2018 14:04

250,000 first trade and 241,929 latest trade.

[dave4545] 26/11/2018 13:59

Cannot see that trade supertag?

[supertag] 26/11/2018 13:54

That's me in for just under 500,000 shares @ 0.05082p

[dave4545] 26/11/2018 09:22

Heading back to 0.6p levels soon I reckon.

[buywell3] 26/11/2018 06:04

............ Mitigation of Risk ..................

This might be my last post for a while as I have said pretty much what I want to say for now on SKIN , I will return when RNS's or updates provide areas for me to comment on.



I assume a little company like Integumen gets a client to sign a contract with some kind of disclaimer so that Integumen can't have its @rse sued off it, probably a standard clause for most CRO's ( Contract Research Organisations )

I also assume Integumen carry insurance V in case of legal claims made against them by a miffed client.



One area that might lead to problems is what are the exact chemical properties of the test product supplied by the client.


I also assume that the client also supplies the molecular structure ( also gives all the different chemicals/elements/metals present in the test sample.

Such data as the above would for example enable the data to be fed into Labskin A1 and hey presto the results datasets pop out soon after.

But in a real test sample of material can Integumen believe 100% what data the client supplies regarding the molecular construction of the product to be tested ?

Many CRO's use a good quality Mass Spectrometer to give them the data as to what molecules are indeed present in a test sample , they don't come cheap , new $250,000 for a good one ... but they can be acquired used and in working condition or perhaps another CRO paid to supply the data required.

I say this because IMO Integumen need to be 100% sure of what is in the test sample

The use of a Mass Spec does this ... maybe some smaller companies are not 100% sure themselves of what the molecular structure of their cosmetic product is ... in fact the more I think about it ... because it has not been a legal requirement from the FDA to supply such data ... in the majority of cases it is most probable that the molecular structure and Chemicals/elements/metals present within cosmetic products.


Perhaps , if this is the case , the provision of a Mass Spec service to add to the results could also be an option ... Diamond service ?


The mitigation of risk re the test results supplied to a client are dependent upon what is being tested.

Both parties involved have to agree what that is ... in many cases I don't think many Cosmetics Manufacturers know 100% except they know the ingredients that went into the mix.

But as we know ... when various chemicals/elements/liquids/metals are mixed together reactions happen

Reactions which produce other chemical compounds ... hence this post

cheers for now

[dave4545] 25/11/2018 21:56

Love your posts buywell3

Wonder when others will noticed the potential ?

[buywell3] 25/11/2018 21:29

GB noted but please don't get yourself in trouble re posting , I confirm again for anyone interested that buywell likes Labskin ... comments buywell makes are to try to help if possible.



.......... Labskin Services : pricing and Supply V Demand ..........

This post focuses on Labskin V Cosmetics industry ( Transdermal and Topical drugs will be addressed in another )


I am now convinced that Labskin is currently entering into a 'sweet-spot' regarding the testing of cosmetics products due to

1. Animal Testing bans within that industry now starting to go worldwide

2. USA states now starting to implement animal testing bans ( at long last )

3. FDA actions to answer the call to become involved in the regulation/approvals of cosmetic products , proof

''The FDA (Food and Drug Administration) is launching a survey of safety practices and manufacturing standards targeting the cosmetics industry and taking a detailed look at a sector that includes an estimated 900 companies.''





Orders for Integumen (SKIN) Labskin services are starting to ramp up as recent RNS's indicate


More staff and increased space is needed to meet increasing demand as the last RNS indicates

Use of Proceeds

In addition to the debt facility provided by Cellulac, announced on the 11 October 2018, the Company plans to use the net proceeds of the Subscription and Placing:

- to support the accelerating growth of Labskin,
- to add more Laboratory space and leasing equipment for increased Labskin production,
- to roll out of Labskin Association Workshops,
- to roll out of the Labskin AI platform,
- to promote Algzym Technology as part of the Commercial Technology Agreement with Cellulac


SKIN could now most likely be in a position of turning away work due to it being a small fledgling company and demand for its services now starting to swamp it.

What a lovely position to be in

When demand exceeds supply the the price goes up.

This is where GB has the nous I hope to get the pricing adjusted to meet the increase in demand

It is a delicate balancing act that is required in such a situations so that Labskin Labs are kept 100% busy and client requests for services are JUST met but perhaps a few may shy away from ordering in the process of getting the pricing tweaked just right ... I like the bronze/silver/gold idea as it gives more flexibility re pricing adjustment.

How many different cosmetic products are there ? ie what is the potential reach in the market for Labskin within the Cosmetics Industry ?



Cosmetic products

Cosmetics are substances or products used to enhance or alter the appearance of the face or fragrance and texture of the body. Many cosmetics are designed for use of applying to the face, hair, and body. They are generally mixtures of chemical compounds; some being derived from natural sources (such as coconut oil), and some being synthetics or artificial.[1] Cosmetics applied to the face to enhance its appearance are often called make-up or makeup. Common make-up items include: lipstick, mascara, eye shadow, foundation. Whereas other common cosmetics can include skin cleansers and body lotions, shampoo and conditioner, hairstyling products (gel, hair spray, etc.), perfume and cologne. skin-care creams, lipsticks, eye and facial makeup, towelettes, deodorants, lotions, powders, perfumes, baby products, bath oils, bubble baths, bath salts, and body butters; to the hands/nails: fingernail and toe nail polish, and hand sanitizer

The list is almost endless ... and is still growing

Interestingly soap is not included ... but will soap manufacturers take the chance and not get their products tested in case the FDA looks at them too ?





In the USA alone the FDA are going to take a look at 900 companies ... so say around 1,000 companies are involved that might want testing carried out.

How many different cosmetics products does each company make ?

A typical large company like Proctor and Gamble make circa 350 products regarding Facial Skin Care , Body Care and Hair care .



When one looks at all the other areas of cosmetics products one can see we are talking about many Millions of individual cosmetic products for testing from just the USA.


I would imagine from my experience of other companies involved with ADMET and the provision of biological testing services , that the big companies are first movers in getting their products tested ASAP.

These have the deepest pockets, and its a shame but they never let their names get used by the service providers. Hence SKIN has to say ''Fortune 500 company'' or some such comment.

Integumen - Interim Results - Proactiveinvestors (UK)
hxxps://proactiveinvestors.co.uk
Aug 29, 2018 - Integumen and Cellulac plc entered into a commercial agency agreement .... That list includes small, medium and Fortune 500 companies.

What a rubber stamping of what Labskin provide by such companies

The Fortune 500 is an annual list compiled and published by Fortune magazine that ranks 500 of the largest United States corporations by total revenue for their respective fiscal years. The list includes publicly held companies, along with privately held companies for which revenues are publicly available.


But I do have a concern , and that is with the provision of Labskin AI v other Labskin service such as in-vitro testing


The FDA still places much importance to in-vitro testing regarding pre-clinical trials ...first paragraph ( IND is Investigational New Drug ) ie before moving onto human clinical trials a IND must be provided giving the FDA all the pre-clinical testing results , ( FDA compliant of course ) or else no chance of success.



IND Applications for Clinical Investigations: Pharmacology and Toxicology (PT)

This component of an IND application is expected to contain information about pharmacological and toxicological (laboratory animals or in vitro) studies on the basis of which the sponsor of the IND application has concluded that it is reasonably safe to conduct the proposed clinical investigations.

So the FDA likes BOTH predictive testing/computer modelling which falls into the Labskin AI offering and also the FDA likes in-vitro testing also which Labskin is being used for .

So SKIN have both bases covered

The pricing of each is critical as a client might go with one type of test ie predictive ... and not the other.

Hence Labskin AI pricing must not be cheaper to stop Labskin in-vitro testing growth.

A way must be found to offer BOTH services in a complementary fashion so that the client covers all his bases ... perhaps a Platinum offering ?

[mulligut] 25/11/2018 10:51

Interesting information that is out in the public domain and now here for investors to read as part of their research. I wonder how many cosmetic companies actually know about this.

[74tom] 25/11/2018 10:09

I’m also looking forward to learning more about the Rinolab collaboration, as I believe this partnership can take Labskin to the next level.

The Rinolab website is worth a look too;


hxxps://www.rinolab.com/about/

From the 17 September RNS

Fin Murray (CEO of RinoCloud Ltd - RinoLab) commented:

"The RinoLab Team have developed a range of algorithms for the dissimination of big data specifically from scientific sources and is perfectly suited to analysing Labskin data to unlock trends and patterns that would normally be missed on a manual review. Using RinoLab, Labskin AI clients are provided with suggested alterations to improve product formulations to increase efficiency and efficacy. RinoLab analysis provides supporting data for the "Product Information File" required by cosmetic brand and skin care companies, prior to product launches in the US and EU markets.

[74tom] 25/11/2018 09:52

Great research Buywell3, I wasn’t aware that cosmetics weren’t strictly regulated by the FDA, surprising/disturbing in equal measures as you say!

I thought the below extract was a particularly good summary - hope you don’t mind me re-posting it..

“It looks like the FDA is going to get involved ... which is why IMO orders for Integumen (SKIN) Labskin services are rising at what I do hope seems to be an exponential rate


Manufacturers of Cosmetic Products have been fully aware now for a year or two that the FDA are going to have to become involved in the Cosmetics Industry and are thus starting to take action now ... to make sure

1. Their existing products are not going to become a problem for them and
2. Their new products are also not going to become a problem.”

The acceleration in Labskin revenue has been really impressive, add in the imminent launch of AI machine learning to the changing regulatory environment that you have described & it will be fascinating to see how quickly it can continue to grow...

[buywell3] 24/11/2018 20:53

Integumen people ... this is an important link

Status of Human Dermal Safety Testing in Topical Drug Product ... - FDA


Sep 10, 2018 - Safety Testing in Topical Drug. Product Development. Hon-Sum Ko, MD, FACP. Medical Officer. Division of Dermatology and Dental Products.



.............. SKIN and the importance of the FDA .................


In my last post I highlighted the move that is coming from the FDA to get away from the use of animals in the development of new drug compounds.

The main drivers will be

1. Public opinion : which is growing regarding the use of animals and a recent Gallup poll showed 44% now want a ban on the use of animals. (see my last post)


and

2. The huge cost to big Pharma of the use of animals and the cost associated to taking hits when the FDA has to withdraw a drug approval ... sometimes several years after joe public has been the guinea pigs getting damaged and killed by an unsafe FDA approved drug. In excess of $1 Billion per drug to $2 Billion per dug currently.

and

3. The legal costs due to class actions which happen more often than one might think. These costs also run in the $ Billions for a blockbuster (widely used) drug.




SKIN are going to benefit from working on new drug compounds that will be topical drugs , I also would like to see the Labskin website highlight 'Transdermal delivery' separately from topical drug delivery as IMO there are two distinct markets to sell into transdermal drug manufacturers and topical drug manufacturers

The FDA sees transdermal drug manufacture as a separate area

FDA Guidance Document: Transdermal Drug Delivery Systems – BIO


FDA-2010-D-0246: Draft Guidance for Industry on Residual Drug in Transdermal and Related Drug Delivery Systems


Good for SKIN is that

Transdermal Drug Delivery Gains Traction | Pharmaceutical Technology



May 4, 2015 - Advances in transdermal drug delivery, particularly with microneedles, are enabling a wider range of drugs to be delivered through the skin


A transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body.


Some great technical data here re the skin and transdermal drugs



with lastly where below in 6. , TDD is Transdermal Drug Delivery

6. Conclusions

In conclusion, the TDD sector continues to grow and develop with rapid expansion in fundamental knowledge feeding industrial development. In time, it is hoped that technological advancements in TDD will lead to enhanced disease prevention, diagnosis and control, with concomitant improvement in health-related quality of life for patients worldwide. To this end, this review has charted the development of numerous novel TDD methodologies, highlighting the advantages and disadvantages of each approach. Due to the exponential growth in investment and interest in MN technologies and the numerous associated advantages of this approach, particular attention was paid to this TDD system.


So in short the use of Transdermal Drugs is set to increase bigtime ( I posted on this here a few weeks back) re Global Market Forecasts for TDD average a CAGR of around 9.5% to 2025 from now.



Topical Drug manufacturers are treated differently by the FDA than Transdermal Drug manufacturers

Status of Human Dermal Safety Testing in Topical Drug Product ... - FDA




Sep 10, 2018 - Safety Testing in Topical Drug. Product Development. Hon-Sum Ko, MD, FACP. Medical Officer. Division of Dermatology and Dental Products.

From this above FDA link there are several more Meta Tags that IMO should be incorporated in the new www.Labskin.co.uk website ... which has the potential to be a big winner of orders if developed properly.

These 4 search terms for Google use (Meta Tags) would be

• Cumulative irritancy potential,
• Contact sensitization potential,
• Photoirritation (phototoxicity) potential*, and
• Photoallergenicity (photocontact allergy) potential*.

It is worth noting that of the 56 topical drug products approved by the FDA between 2003 and 2017 these were the biggest types to get FDA approval

GEL 16 ....................... ie 28.5%
CREAM 10 .................... ie 17.8%
EMULSION, AEROSOL FOAM 8 .. ie 14.3%

Over 60% of Topical drug FDA approvals in that period were in those above 3 delivery areas.

5 other Meta Tags would be

Cumulative irritancy

Contact sensitization

Combined irritancy/sensitization

Photoirritation

Photoallergenicity


So to sum up ... it would be wise to use all relevant FDA specified Human Dermal Safety Tests (DST's) as www.labskin.co.uk Meta Tags as drug manufacturers of such products will be having to source in many cases providers of such services ... of which Integumen (SKIN) is.


It is also interesting to note that the FDA guy running the workshop for big pharma attendees gave them these top 2 things to do


Issues for Discussion (1)

• 1. Discuss your perspective on the role of current human
dermal safety studies for the clinical development of topical
drug products.

• 2. In light of the nonclinical assays listed in the ICH S10 guidance document to assess photosafety (e.g., in vitro 3T3 NRU-PT assay, reconstructed human skin models, in vivo animal assay), discuss your perspective on the role of human photosafety studies (i.e., photoirritation and photoallergenicity clinical studies).


Which is where ... in effect ... Labskin gets a plug as it is a reconstructed human skin model

Venn also get a plug re their in-vitro assays that they carry out using Labskin ... I would like to see these in-vitro services moved over to Labskin so that they could be added to the new Labskin.co.uk website ... confusing for clients to have to work to two different sets of people about the use of Labskin. Also the added value of in-vitro assays using Labskin wants to be added to SKIN revenue and profits.

Studying the Human Skin Microbiome Using 3D In Vitro Skin Models
www.innovenn.co.uk/.../2015-Studying-the-Human-Skin-Microbiome-Using-3D-In-...
by RA Bojar - ‎Cited by 5 - ‎Related articles

Labskin is a commercial 3D in vitro skin model based on the original Leeds Model specifically developed for studying interactions between the skin and its microbiome. ... Increasing the complexity of 3D in vitro reconstructed human skin models, raises a number of issues that affect their reliability and predictability.


I have lots more to say ... but IMO SKIN must ensure that its new website and service offerings are geared to FDA Guidance to the Pharma Topical and Transdermal manufacturers as they will have to be FDA compliant to get FDA approval ... simple as.

[dave4545] 24/11/2018 08:55

Nice post. Potential is enormous here at current £1.5 mil cap

[buywell3] 24/11/2018 01:42

SKIN is an ethical investment regarding Labskin ... which is why I am here and posting

All my investments have been made based upon an ethical premise ... obviously the ones that have the potential to make me the most money rate higher up the list.

Ethical companies that have no potential to make profits don't make the list.


I have posted re the FDA and animal testing regarding the current pre clinical testing of new drug compounds and how science has moved on since the FDA began the use of animals for pre clinical testing over half a century ago.



The FDA have recently said this


''There are still many areas where animal testing is necessary and non-animal testing is not yet a scientifically valid and available option. However, FDA has supported efforts to reduce animal testing.

In addition, FDA has research and development efforts underway to reduce the need for animal testing and to work toward replacement of animal testing.''


I don't agree with the FDA ... there are in fact a plethora of well proven ADMET tests existing that give much better results than the 50/50 coin flip that animals currently give.


One of the worst tests is the Acute Toxicity test the T in ADMET


In this test an animal is given an increasing dose of the drug compound under test over a period of around 4 weeks to a max of around 8 weeks till the animal dies,

The level then gets recorded.... big deal.... what good is the number ? it's a dog or cat or rabbit , also maybe a rat or mouse or hamster.


This test along with other pre clinical tests is why so many humans are adversely affected during the human clinical trials of a new drug compound that follow.

Now a law suit has been filed against the FDA regarding 150 human deaths in clinical trials since 2014




Could cause legal claims for big Pharma doing clinical trials as well


It is also why the FDA have to recall so many drugs years after they have been approved due to the accumulated damage to organs or death ...



Class legal actions result ... Big Pharma companies have to pay $Billions in legal fees plus the drug development of a new compound costs around $2 Billions and takes 12 to 14 years.


So animal is costing the Pharma Industry $Billions ... which is why many are cutting back on their developments of new drug pipelines and instead are buying other smaller Pharma companies that are into final phase 3 human approval just before FDA approval is likely.


Clearly this can't carry on as the number of likely buyout targets is running out.

Why are animals used for testing medical products?


Note the FDA page was .... Last Updated: 08/22/2018 ... so things are happening


But the USA Government won't do anything till the majority of voters don't agree with animal testing for new drug development


Interestingly this is closer than you may think

As of last May, a Gallup poll showed that 44 percent of adults in the U.S. believe medical testing on animals is “morally wrong,” up from 26 percent in 2001






Isn't it amazing that those in drug manufacture are not actively lobbying the FDA to get things changed ?

Why don't they

Because the provision and use of animals in animal testing of new drug compounds is a multi $ Billion industry in itself.

This is how bad things have become :


The National Institutes of Health reports that 95 out of every 100 drugs that successfully pass animal trials and go into human clinical testing fail during the human clinical trial phase.




The changes in the Cosmetics Industry regarding the banning of animals for testing purposes have made the FDA look very bad ... further changes will put the spotlight yet brighter on the FDA for example

In Feb 2018 the European Parliament’s Environment Committee (Envi) voted to advocate for a worldwide ban on animal testing for cosmetics by 2023.

The US does not have a formal requirement for animal testing of cosmetic products, but the Food and Drug Administration (FDA) does require companies to test across a range of toxicological endpoints in order to prove safety.

According to the FDA's website, animal testing by manufacturers, seeking to market new products, may be used to establish product safety. "In some cases, after considering available alternatives, companies may determine that animal testing is necessary to assure the safety of a product or ingredient," it says.

Francine Lamoriello, executive vice president of global strategies for the Personal Care Products Council (PCPC), told Chemical Watch, the cosmetics industry has invested "hundreds of millions of dollars over the past several decades to develop scientifically valid alternative safety testing methods".

She added that the PCPC encouraged FDA approval of alternatives to animal testing "as part of its principles for federal cosmetics regulatory modernisation" and was committed to "the development of additional alternative testing methodologies".






Things are starting to happen at long last in America ....


California Animal Testing Ban for Cosmetics

USA October 9 2018

California law currently prohibits manufacturers and contract testing facilities in California from testing cosmetics on animals if alternative test methods have been scientifically validated. A new California law now imposes similar animal testing prohibitions on manufacturers that import cosmetics into the state.

The Prohibition

On and after January 1, 2020, a manufacturer may not import for profit, sell or offer for sale in California any cosmetic that was developed or manufactured using an animal test that was conducted or contracted by the manufacturer, or any supplier of the manufacturer, subject to certain exceptions.




So it looks like state by state animal testing in the USA within the cosmetics industry is going to soon end ... hence the orders for Labskin look set to rise further and a USA based agent for SKIN might be needed ... perhaps for starters a California based small cap pre clinical testing company ( non animal that is )

[dave4545] 23/11/2018 21:46

hxxps://labskin.co.uk/?utm_source=mc&;utm_medium=email&utm_campaign=NS_Microflora

Labskin’s Fibrin Gel matrix is the only commercially available laboratory-grown full thickness human skin test platform that creates new collagen production and shows the impact on your skin’s microflora balance of cosmetic and skin care products.
Specifically developed animal-free test solution to host harmful skin bacteria which allows the introduction of toxins, bacteria, viruses, and other foreign substances that trigger an immune response.